IMPDH Inhibitors: Discovery of Antiviral Agents against Emerging Diseases

Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats

Volumn , Issue , 2005, Pages 178-202

  Nair, Vasu ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Cowpox virus; Ebola virus; Filovirus; Marburg virus; Monkeypox virus; Orthopoxvirus; Smallpox; Vaccinia virus; Variola virus

Indexed keywords

EID: 84890979835     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471716715.ch8     Document Type: Chapter

References (79)

1. Fenner, F. Poxviruses, in Fields Virology, Fields, B. N., Knipe, D. M., Howley, P. M. (eds.). Lippincott-Raven, Philadelphia, 1996, pp. 2673-2702.
2. LeDuc, J. W.; Damon, I.; Meegan, J. M.; Relman, D. A.; Huggins, J.; Jahrling, P. B. Smallpox research activities: U.S. interagency collaboration, 2001. Emerging Infect. Dis. 2002, 8, 743-745.
3. Heymann, D. L.; Szczeniowski, M.; Esteves, K. Re-emergence of monkeypox in Africa: a review of the past six years. Br. Med. Bull. 1998, 54, 693-702.
4. Jezek, Z.; Szczeniowski, M.; Paluku, K. M.; Mutombo, M. Human monkeypox: clinical features of 282 patients. J. Infect. Dis. 1987, 156, 293-298.
5. Hooper, J. W.; Thompson, E.; Wilhelmsen, C.; Zimmerman, M.; Ichou, M. Ait; Steffen, S. E.; Schmaljohn, C. S.; Schmaljohn, A. L.; Jahrling, P. B. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 2004, 78, 4433-4443.
6. Bremen, J.; Henderson, D. A. Poxvirus dilemmas-monkeypox, smallpox and biological terrorism. N. Engl. J. Med. 1998, 339, 556-559.
7. Henderson, D. A. Bioterrorism as a public health threat. Emerging Infect. Dis. 1998, 4, 488-492.
8. Henderson, D. A. The looming threat of bioterrorism. Science 1999, 283, 1279-1282, and references therein.
9. Fenner, F.; Henderson, D. A.; Arita, I.; Jezek, Z.; Ladnyi, I. D. Smallpox and Its Eradication, World Health Organization, Geneva, 1988.
10. Moss, B. Poxviridae: the viruses and their replication, in Fields Virology, B. N. Fields, D. M. Knipe, and P. M. Howley (eds.). Lippincott-Raven, Philadelphia, 1996, pp. 2637-2671.
11. Bray, M. Filoviridae, in Clinical Virology, Richman, D. R., Whitley, R. J., Hayden, F. G. (eds.). ASM Press, Washington, Dc, 2002, pp. 875-890.
12. Sanchez, A., Peter, C. J., Rollin, P., Ksiazek, T. G., Murphy, F. A. Filoviridae: Marburg and Ebola viruses, in Fields Virology, Fields, B. N., Knipe, D. M., Howley, P. M. (eds.). Lippincott-Raven, Philadelphia, 2001, pp. 1161-1176.
13. Bray, M.; Paragas, J. Experimental therapy of filovirus infections. Antiviral Res. 2002, 54, 1-17.
14. Hay, J.; Bartkoski, M. J. Jr. Pathogenesis of viral Infections, in Chemotherapy of Viral Infections, Came, P. E., Caliguiri, L. A. (eds.). Springer-Verlag, Berlin, 1982, pp. 1-91.
15. Kerr, K. M.; Hedstrom, L. The roles of conserved carboxylate residues in IMP dehydrogenase and identification of a transition state analog. Biochemistry 1997, 36, 13365-13373.
16. Wang, W.; Hedstrom, L. Kinetic mechanism of human inosine 5'-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products. Biochemistry 1997, 36, 8479-8483.
17. Hedstrom, L. IMP dehydrogenase: mechanism of action and inhibition. Curr. Med. Chem. 1999, 6, 545-560.
18. Kerr, K. M.; Digits, J. A.; Kuperwasser, N.; Hedstrom, L. Asp338 controls hydride transfer in E. coli IMP dehydrogenase. Biochemistry 2000, 39, 9804-9810.
19. 0-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Prog. Nucleic Acid Res. Mol. Biol. 1998, 61, 181-209.
20. St. Georgiev, V. Enzymes of the purine metabolism: inhibition and therapeutic potential. In Annals of New York Academy of Sciences, Volume 685, St. Georgiev, V.; Yamaguchi, H. (eds.). New York Academy of Sciences, New York, 1993, pp. 207-216.
21. Pankiewicz, K. W. Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents. Exp. Opin. Ther. Patents 1999, 9, 55-65.
22. Natsumeda, Y.; Carr, S. F. Human type I and II IMP dehydrogenases as drug targets. In Annals of New York Academy of Sciences, Volume 696, Allison, A. C.; Lafferty, K. J.; Fliri, H. (eds.). New York Academy of Sciences, New York, 1993, pp. 88-93.
23. Pani, A.; Marongiu, M. E.; Pinna, E.; Scintu, F.; Perra, G.; De Montis, A.; Manfredini, S.; La Colla, P. In vitro and in vivo antiproliferative activity of IPCAP, a new pyrazole nucleoside analog. Anticancer Res. 1998, 18, 2623-2630.
24. Kosugi, Y.; Saito, Y.; Mori, S.; Watanabe, J.; Baba, M.; Shigeta, S. Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho and paramyxoviruses. Antiviral Chem. Chemother. 1994, 5, 366-371.
25. Franchetti, P.; Cappellacci, L.; Grifantini, M.; Barzi, A.; Nocentini, G.; Yang, H.; O'Connor, A.; Jayaram, H. N.; Carrell, C.; Goldstein, B. M. Furanfurin and thio-phenfurin: two novel tiazofurin analogues. Synthesis, structure, antitumor activity, and interactions with inosine monophosphate dehydrogenase. J. Med. Chem. 1995, 38, 3829-3837.
26. Xiang, B.; Taylor, J. C.; Markham, G. D. Monovalent cation activation and kinetic mechanism of inosine 5'-phosphate dehydrogenase. J. Biol. Chem. 1996, 271, 1435-1440.
27. Antonino, L. C.; Wu, J. C. Human IMP dehydrogenase catalyzes the dehalogenation of 2-fluoro-and 2-chloroinosine 5'-monophosphate in the absence of NAD. Biochemistry 1994, 33, 1753-1759.
28. Zhang, H.-Z.; Rao, K.; Carr, S. F.; Papp, E.; Straub, K.; Wu, J. C.; Fried, J. Rationally designed inhibitors of inosine monophosphate dehydrogenase. J. Med. Chem. 1997, 40, 4-8.
29. Franchetti, P.; Grifantini, M. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr. Med. Chem. 1999, 6, 599-614.
30. Goldstein, B. M.; Colby, T. D. IMP dehydrogenase: structural aspects of inhibitor binding. Curr. Med. Chem. 1999, 6, 519-536.
31. De Clercq, E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 2001, 14, 382-397.
32. De Clerq, E. Strategics in the design of antiviral drugs. Nat. Rev. Drug Disc. 2002, 11, 13-25.
33. Smith, R. A.; Kirkpatrick, W. (eds.). Ribavirin. A Broad Spectrum Antiviral Agent, Academic Press, New York, 1980.
34. Smee, D. F.; Huggins, J. W. Potential of the IMP dehydrogenase inhibitors for antiviral therapies of poxvirus infections. Antiviral Res. 1998, A89.
35. Goswami, B. B.; Borek, E.; Sharma, O. K.; Fujitaki, J.; Smith, R. A. The broad-spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 1979, 89, 830-836.
36. Franchetti, P.; Cappellacci, L.; Grifantini, M. IMP dehydrogenase as a target of antitumor and antiviral chemotherapy. Il Farmaco 1996, 51, 457-469.
37. Wang, W.; Papov, V. V.; Minakawa, N.; Matsuda, A.; Biemann, K.; Hedstrom, L. Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate. Biochemistry 1996, 35, 95-101.
38. Minakawa, N.; Matsuda, A. Design of inosine 5'-monophosphate dehydrogenase inhibitors: synthesis and biological activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives. Curr. Med. Chem. 1999, 6, 615-628.
39. Pal, S.; Bera, B.; Nair, V. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by the antiviral compound, 2-vinylinosine. Bioorg. Med. Chem. 2002, 10, 3615-3618.
40. Holland, J. J.; Domingo, E.; de la Torre, J. C.; Steinhauer, D. A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 1990, 64, 3960-3962.
41. Lee, C. H.; Gilbertson, D. L.; Novella, I. S.; Huerta, R.; Domingo, E.; Holland, J. J. Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. J. Virol. 1997, 71, 3636-3664.
42. Crotty S; Maag, D.; Arnold, J. J.; Zhong, W.; Lau, J. Y.; Hong, Z.; Andino, R.; Cameron, C. E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000, 6, 1375-1379.
43. Sierra, S; Davila M.; Lowenstein, P. R.; Domingo, E. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J. Virol. 2000, 74, 8316-8323.
44. Davis, G. L.; Esteban-Mur, R.; Rustgi, V.; Hoefs, J.; Gordon, S. C.; Trepo, C.; Shiffman, M. L.; Zeuzem, S.; Craxi, A.; Ling, M. H.; Albrecht, J. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998, 339, 1493-1499.
45. McHutchison, J. G.; Gordon, S. C.; Schiff, E. R.; Shiffman, M. L.; Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M. H.; Cort, S.; Albrecht, J. K. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998, 339, 1485-1492.
46. Wyde, P. R. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 1998, 39, 63-79.
47. Crotty, S.; Cameron, C. E.; Andino, R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl Acad. Sci. U.S.A. 2001, 98, 6895-6900.
48. Konno, Y.; Natsumeda, Y.; Nagai, M.; Yamaji, Y.; Ohno, S.; Suzuki, K.; Weber, G. Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines. J. Biol. Chem. 1991, 266, 506-509.
49. Carr, S. F.; Papp, E.; Wu, J. C.; Natsumeda, Y. Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem. 1993, 268, 27286-27290.
50. Hager, P. W.; Collart, F. R.; Huberman, E.; Mitchell, B. S. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins: purification and characterization of inhibitor binding. Biochem. Pharmacol. 1995, 49, 1323-1329.
51. Schalk-Hihi, C.; Zhang, Y.-Z.; Markham, G. D. The conformation of NADH bound to inosine 5'-monophosphate dehydrogenase determined by transferred nuclear Overhauser effect spectroscopy. Biochemistry 1998, 37, 7608-7616.
52. Miyamoto, T.; Matsuno, K.; Imamura, M.; Kim, S.-I.; Honjon, K.; Hatano, S. Purification and some properties of IMP dehydrogenase of Bacillus cereus. Microbiol. Res. 1998, 153, 23-27.
53. Carson, M. Ribbons 2.0, IMPDH. J. Appl. Crystallogr. 1991, 24, 958-961.
54. Colby, T. D.; Vanderveen, K.; Strickler, M. D.; Markham, G. D.; Goldstein, B. M. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 3531-3536.
55. Zhang, R.-G.; Evans, G.; Rotella, F. J.; Westbrook, E. M.; Beno, D.; Huberman, E.; Joachimiak, A.; Collart, F. R. Characteristics and crystal structure of bacterial inosine-5'-monophosphate dehydrogenase. Biochemistry 1999, 38, 4691-4700.
56. Risal, D.; Strickler, M. D.; Goldstein, B. M. The ternary complex of the human type II inosine monophosphate dehydrogenase with 6-Cl IMP and NAD. Protein Data Bank 2004 in press.
57. Naesens, L.; Snoeck, R.; Andrei, G.; Balzarini, J.; Neyts, J.; De Clercq, E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother. 1997, 8, 1-23.
58. Huggins, J. W.; Martinez, M. J.; Hartmann, C. J.; Hensley, L. E.; Jackson, D. L.; Kefauver, D. F.; Kulesh, D. A.; Larsen, T.; Miller, D. M.; Mucker, E. M.; Shamblin, J. D.; Tate, M. K.; Whitehouse, C. A.; Zwiers, S. H.; Jahrling, P. B. Successful cidofovir treatment of smallpox-like disease in Variola and monkeypox primate models. Antiviral Res. 2004, 62, A57.
59. Srivastava, P. D.; Pickering, M. U.; Allen, O. B.; Streeter, D. G.; Campbell, M. T.; Witkowski, J. T.; Sidwell, R. W.; Robins, R. K. Synthesis and antiviral activity of certain thiazole C-nucleosides. J. Med. Chem. 1977, 20, 256-262.
60. Cooney, D. A.; Jayaram, H. N.; Gebeyehu, G.; Betts, C. R.; Kelley, J. A.; Marquez, V. E.; Johns, D. G. The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analog of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem. Pharmacol. 1982, 31, 2133-2136.
61. Nair, V.; Ussery. M. A. New hypoxanthine nucleosides with RNA antiviral activity. Antiviral Res. 1992, 19, 173-178.
62. Preobrazhenskaya, M. N.; Korbukh, I. A. xxx. In Chemistry of Nucleosides and Nucleotides, Vol. 3, Townsend, L.B. (ed.). Plenum Press, New York, 1994, pp. 1-105, and references therein.
63. Nair, V.; Richardson, S. G. Modification of nucleic acid bases via radical intermediates: synthesis of dihalogenated purine nucleosides. Synthesis 1982, 670-672.
64. Nair, V.; Richardson, S. G. The utility of purinyl radicals in the synthesis of base-modified nucleosides and alkyl purines: 6-amino group replacement by H, Cl, Br, and I. J. Org. Chem. 1980, 45, 3969-3974.
65. Nair, V.; Young, D. A.; DeSilvia, R. G. 2-Halogenated purine nucleosides: synthesis and reactivity. J. Org. Chem. 1987, 52, 1344-1347.
66. Nair, V.; Turner, G. A.; Buenger, G. S.; Chamberlain, S. D. New methodologies for the synthesis of C-2 functionalized hypoxanthine nucleosides. J. Org. Chem. 1988, 53, 3051-3057.
67. Nair, V.; Turner, G. A.; Chamberlain, S. D. Novel approaches to functionalized nucleosides via palladium-catalyzed cross-coupling with organostannanes. J. Am Chem. Soc. 1987, 109, 7223-7224.
68. Minakawa, N.; Takeda, T.; Sasaki, T.; Matsuda, A.; Veda, T. Nucleosides and nucleotides. Synthesis and antitumor activity of 5-ethynyl-1-beta-D-ribofuranosyl-imidazole-4-carboxamide (EICAR) and its derivatives. J. Med. Chem. 1991, 34, 778-786.
69. Srivastava, P. C.; Robins, R. K. Synthesis and antitumor activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide and related derivatives. J. Med. Chem. 1983, 26, 445-448.
70. Jayaram, H. N.; Ahluwalia, G. S.; Dion, R. L.; Gebeyehu, G.; Marquez, V. E.; Kelley, J. A.; Robins, R. K.; Cooney, D. A.; Cooney, D. A.; Johns, D. G. Conversion of 2-beta-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem. Pharmacol. 1983, 32, 2633-2636.
71. Streeter, D. R.; Robins, R. K. Comparative in vitro studies of tiazofurin and a selenazole analog. Biochem. Biophys. Res. Commun. 1983, 115, 544.
72. Tarumi, Y.; Takebayaski, Y.; Atsumi, T. Studies on imidazole derivatives and related compounds. 4. Synthesis of O-glycosides of 4-carbamoylimidazolium-5-olate. J. Hetero-cycl. Chem. 1984, 21, 849-854.
73. Kosugi, Y.; Saito, Y.; Mori, S.; Watanabe, J.; Baba, M.; Shigeta, S. Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against ortho-and paramyxoviruses. Antiviral Chem. Chemother. 1994, 5, 366-371.
74. Suhadolnik, R. J. Nucleosides as Biological Probes, Wiley, New York, 1979, pp. 149-154.
75. Nair, V.; Bera, B.; Kern, E. R. Synthesis and antiviral activities of 2-functionalized purine ribonucleosides. Nucleosides Nucleotides Nucleic Acids 2003, 22, 115-127.
76. Nair, V.; Kamboj, R. C. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by 2-[2-(Z)-fluorovinyl] inosine 5'-monophosphate. Bioorg. Med. Chem. Lett. 2003, 13, 645-647.
77. Nair, V.; Kern, E. R.; Bera, B. Antiviral ribonucleosides: inhibitors of inosine monophosphate dehydrogenase. Antiviral Res. 2002, 53, A63.
78. Nair, V.; Story, S.; Gupta, M.; Bonsu, E. Antiviral ribonucleosides: inhibitors of inosine monophosphate dehydrogenase. Antiviral Res. 2004, 62, A72.
79. Bishop, D. H. Virion polymerases. In Comprehensive Virology, Vol. 10, Plenum Press, New York, 1977, pp. 117-253.